Trial Profile
Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 25 May 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2018 New trial record